U1355 RAMO-IT - Molecular Radiotherapy and Therapeutic Innovations
Major publications

• Bockel S, El Aichi M, Sun R, Benzazon N, de Kermenguy F, Veres C, Satragno C, Bidault F, Garcia G, Dhermain F, Deutsch E, Robert C. Integration of white matter tracts in stereotactic brain radiotherapy treatment planning with a fully automated atlas-based pipeline. Comput Biol Med. 2026
• Maury P, Sayous Y, Marnaoui R, Loiseau C, Khalladi N, Sun X-S, Bourhis J, Vernerey D, Falcoz A, Thariat J, Stereotactic Ablative Radiotherapy (SABR) Quality and Survival of Patients with Head and Neck Cancer : a post-hoc analysis of the GORTEC 2014-04 “OMET” Randomised Phase 2 Trial, International Journal of Radiation Oncology Biology Physics, 2025
• Maury P, Sayous Y, Vernerey D, Sun X-S, Bourhis J, Falcoz A, Thariat J, Clustering of Dosimetric Profiles Reveals Distinct Local Control Probabilities after SABR in Oligometastatic Head and Neck Cancer: Insights from the OMET Phase II Trial Quality Assurance Process, Radiotherapy and Oncology, 2025
• Schott C, Said-Mansour I, Maury P, de Kermenguy F, Deutsch E, Colnot J, Robert C. Performance evaluation of EBT3, EBT-XD, and OrthoChromic OC-1 films for reference dosimetry in Ultra-High dose rate electron beams radiotherapy. Phys Med. 2026
• de Kermenguy F, Morel D, El-Aichi M, Barbolosi D, Deutsch E, Robert C. Radiation-Induced Lymphopenia: From Mathematical Modeling Toward Mechanistic Learning. Int J Radiat Oncol Biol Phys. 2026
• Colnot J, Said Mansour I, Schott C, Martin S, Maury P, Dijoud T, Caliendo M, Couturier M, Deutsch E, Robert C, Towards the clinical translation of FLASH radiation therapy: commissioning and performance testing of the new electron UHDR system FLASHKNiFE®, Physica Medica, 2025
• Laurent PA, Shi L, Bouarroudj L, Benzazon N, Gerbé De Thoré M, Liu W, Aglave M, Bergeron P, Naulin F, Sitterlé L, Morel D, Levy A, Clémenson C, Mondini M, Robert C, Meziani L, Deutsch E. Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect. J Immunother Cancer. 2025
• Levy A, Massard C, Michiels S, Deutsch E. Innovative, early-phase clinical trials of drug-radiotherapy combinations. Lancet Oncol. 2025
• Levy A, Morel D, Texier M, Rodriguez-Ruiz ME, Bouarroudj L, Bouquet F, Bustillos A, Quevrin C, Clémenson C, Mondini M, Meziani L, Sun R, Zaghdoud N, Tselikas L, Assi T, Faron M, Honoré C, Ngo C, Verret B, Le Péchoux C, Le Cesne A, Ginhoux F, Massard C, Bahleda R, Deutsch E. Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. Signal Transduct Target Ther. 2025
• Maury P, Hirayama R, Li X, Mahou P, Schanne-Klein MC, Lacombe S, Gref R, Porcel E. Synergistic effect of Gemcitabin-loaded metal organic frameworks nanoparticles with particle therapy. Int J Pharm. 2024
• Chen J, Levy A, Tian AL, Huang X, Cai G, Fidelle M, Rauber C, Ly P, Pizzato E, Sitterle L, Piccinno G, Liu P, Durand S, Mao M, Zhao L, Iebba V, Felchle H, Mallard de La Varende AL, Fischer JC, Thomas S, Greten TF, Jones JC, Monge C, Demaria S, Formenti S, Belluomini L, Dionisi V, Massard C, Blanchard P, Robert C, Quevrin C, Lopes E, Clémenson C, Mondini M, Meziani L, Zhan Y, Zeng C, Cai Q, Morel D, Sun R, Laurent PA, Mangoni M, Di Cataldo V, Arilli C, Trommer M, Wegen S, Neppl S, Riechelmann RP, Camandaroba MP, Neto ES, Fournier PE, Segata N, Holicek P, Galluzzi L, Buqué A, Alves Costa Silva C, Derosa L, Kroemer G, Chen C, Zitvogel L, Deutsch E. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell. 2025
• Assouvie A, Gerbé-de-Thoré M, Torres C, Ménard V, Alfaro A, Deutsch E, Mondini M, Rousselet G. Deleting Trim33 in Myeloid Cells Improves the Efficiency of Radiotherapy through an IFNβ-Dependent Antitumor Immune Response. Cancer Immunol Res. 2025
• Bergeron P, Dos Santos M, Sitterle L, Tarlet G, Lavigne J, Liu W, Gerbé de Thoré M, Clémenson C, Meziani L, Schott C, Mazzaschi G, Berthelot K, Benadjaoud MA, Milliat F, Deutsch E, Mondini M. Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade. Nat Commun. 2024
• Chargari C, Maury P, Texier M, Genestie C, Morice P, Bockel S, Gouy S, Ba M, Achkar S, Lux F, Tillement O, Dufort S, Le Duc G, Debeaumont O, Massard C, Maulard A, Porcel E, Bahleda R, Ammari S, Morel D, Espenel S, Pautier P, Robert C, Deutsch E, Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer, ACS Nano 2024
• de Kermenguy F, Benzazon N, Maury P, Vauclin R, M'hamdi M, Cifliku V, Limkin E, Diallo I, Morel D, Milewski C, Clémenson C, Mondini M, Deutsch E, Robert C. LymphoDose: a lymphocyte dose estimation framework-application to brain radiotherapy. Phys Med Biol. 2024
• Benzazon N, Carré A, de Kermenguy F, Niyoteka S, Maury P, Colnot J, M'hamdi M, Aichi ME, Veres C, Allodji R, de Vathaire F, Sarrut D, Journy N, Alapetite C, Grégoire V, Deutsch E, Diallo I, Robert C. Deep-Learning for Rapid Estimation of the Out-of-Field Dose in External Beam Photon Radiation Therapy - A Proof of Concept. Int J Radiat Oncol Biol Phys. 2024
• Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Mol Cancer. 2024
• Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, Signolle N, Clémenson C, Levy A, Mondini M, Deutsch E. KRAS^G12C inhibition using MRTX1257: a novel radio-sensitizing partner. J Transl Med. 2023
• Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C. A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers. Eur J Nucl Med Mol Imaging. 2023
• Meziani L, Gerbé de Thoré M, Clémenson C, Liu W, Laurent PA, Mondini M, Vozenin MC, Deutsch E. Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOSdownregulation. J Immunother Cancer. 2023
• Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Bockel S, Genestie C, Wu TD, Lux F, Tillement O, Lacombe S, Deutsch E, Robert C, Porcel E. Clinical transfer of AGuIX®-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework. Nanomedicine. 2023
• De Thoré MG, Meziani L, Deutsch E, Mondini M. Cytofluorometric characterization of the myeloid compartment of irradiated mouse tumors. Methods Cell Biol. 2023
• Sun R, Lerousseau M, Briend-Diop J, Routier E, Roy S, Henry T, Ka K, Jiang R, Temar N, Carré A, Laville A, Hamaoui A, Laurent PA, Rouyar A, Robert C, Robert C, Deutsch E. Radiomics to evaluate interlesionheterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. J Immunother Cancer. 2022
• Carré A, Battistella E, Niyoteka S, Sun R, Deutsch E, Robert C. AutoComBat: a generic method for harmonizing MRI-based radiomic features. Sci Rep. 2022
• Hamon P, Gerbé De Thoré M, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Clémenson C, Milliat F, Deutsch E, Mondini M. TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer. 2022
• de Causans A, Carré A, Roux A, Tauziède-Espariat A, Ammari S, Dezamis E, Dhermain F, Reuzé S, Deutsch E, Oppenheim C, Varlet P, Pallud J, Edjlali M, Robert C. Development of a Machine Learning Classifier Based on Radiomic Features Extracted From Post-Contrast 3D T1-Weighted MR Images to Distinguish Glioblastoma From Solitary Brain Metastasis. Front Oncol. 2021
• Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, Carré A, Battistella E, Alvarez Andres E, Niyoteka S, Romano E, Louvel G, Durand-Labrunie J, Bockel S, Bahleda R, Robert C, Boutros C, Vakalopoulou M, Paragios N, Frey B, Soria JC, Massard C, Ferté C, Fietkau R, Ost P, Gaipl U, Deutsch E. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer. 2020
• Meziani L, Gerbé de Thoré M, Hamon P, Bockel S, Andrade Louzada A, Clemenson C, Corré E, Liu W , Dupuy C, Mondini M, Deutsch E. “Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages” J Immunother Cancer 2020
• Mondini M, Loyher PL, Hamon P, Gerbé de Thoré M, Laviron M, Berthelot K, Clémenson C, Salomon BL, Combadière C, Deutsch E, Boissonnas A. “CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance”, Cancer Immunol Res. 2019
• Sun R., EJ Limkin, M. Vakalopoulou, L. Dercle, S. Champiat, S.R. Han, L. Verlingue, D. Brandao, A. Lancia, S. Ammari, A. Hollebecque, J.Y. Scoazec, A. Marabelle, C. Massard, J.C. Soria, C. Robert, N. Paragios, E. Deutsch, C. Ferté. “Radiomics to assess tumor infiltrating CD8 T-cells and response to anti-PD1/PDL1 immunotherapy in cancer patients: an imaging biomarker multi-cohort study”. Lancet Oncology, 2018